In his weekly clinical update, Dr. Griffin informs us about mpox circulation and new vaccine approval, the Marburg virus outbreak in Rwanda, and the largest outbreak of whooping cough in a decade before reviewing the recent statistics on SARS-CoV-2 infection, the WasterwaterScan dashboard, immunity among those over 65th following the 3rd dose of the COVID-19 mRNA vaccine, where to find PEMGARDA, a reminder of how and when to use steroids to treat COVID-19, how well the SARS-CoV-2 rapid antigen test performed, what do when healthcare workers succumb to SARS-CoV-2 infection, the effect of remdesivir on survival and readmission of hospitalized patients, if cognitive impairment following virus infection impairs one’s driving and how long COVID affects Chinese society.

Subscribe (free): Apple Podcasts, RSS, email

Become a patron of TWiV!

Links for this episode

• Undiagnosed MPXV infections are high in men who have sex with men (BMC Infectious Diseases)
• WHO, now a vaccine approval agency, Jynneos for teens  (CIDRAP)
• Mpox outbreak global trends (WHO)
• How to stop Marburg virus (Rwanda Biomedical Centre)
• Marburg virus fact sheet (Rwanda Biomedical Centre)
• Largest whooping cough outbreak in US in a decade (NPR)
• COVID-19 deaths (CDC)
• COVID-19 national and regional trends (CDC)
• Waste water scan for 11 pathogens (WastewaterSCan)
• COVID-19 variant tracker (CDC)
• SARS-CoV-2 genomes galore (Nextstrain)
• Insurance relates to effectiveness and waning of immunity following 3rd dose of mRNA COVID-19 vaccine? (JID)
• New preventive COVID-19 agent (ISDA)
• IDSA Guidelines on the Treatment and Management of Patients with COVID-19 (IDSA)
• Where to get pemgarda (Pemgarda)
• EUA for the pre-exposure prophylaxis of COVID-19 (INVIYD)
• How well do you test: performance of the SARS-CoV-2 antigen rapid detection test (eBioMedicine)
• CDC Quarantine guidelines (CDC)
• NIH COVID-19 treatment guidelines (NIH)
• Infectious Disease Society guidelines for treatment and management (ID Society)
• Drug interaction checker (University of Liverpool)
• Molnupiravir safety and efficacy (JMV)
• Convalescent plasma recommendation for immunocompromised (ID Society)
• What to do when sick with a respiratory virus (CDC)
• When your healthcare provider is infected/exposed with SARS-CoV-2 (CDC)
• Managing healthcare staffing shortages (CDC)
• Steroids, dexamethasone at the right time (OFID)
• Anticoagulation guidelines (hematology.org)
• Remdesivir-associated survival outcomes among immunocompromised patients (CID)
• Remdesivir Effectiveness in Reducing the Risk of 30-day Readmission in Vulnerable Patients (CID)
• Measurement of circulating viral antigens post-SARS-CoV-2 infection (CMI: Clinical Microbiology and Infection)
• DUCI: driving under cognitive influence of COVID-19 (Neurology)
• Long COVID facts and findings: (LANCET: Regional Health Western Pacific)
• Letters read on TWiV 1158
• Dr. Griffin’s COVID treatment summary (pdf)
• Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees

Send your questions for Dr. Griffin to [email protected]